Lipitor Lawsuits Move Forward, as Federal Judge Stays California Case Pending Transfer to Federal Lipitor Diabetes Litigation

Share Article

The Firm is investigating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statin.

Free Case Review
Our Firm has heard from a number of individuals who have made allegations regarding the association between Lipitor and diabetes that echo those included in this case. We will be watching this matter closely.

Lipitor lawsuits ( alleging a link between the use of the statin medication and the development of Type 2 diabetes continue to move forward in courts throughout the U.S., Bernstein Liebhard LLP reports. According to an Order issued on April 30, 2014, U.S. District Judge Michael J. Seng of the Eastern District of California has stayed one Lipitor diabetes lawsuit originally filed in Fresno Superior Court, pending its possible transfer to the federal multidistrict litigation currently underway in U.S. District Court, District of South Carolina. The lawsuit was filed last September on behalf of five women who claim their diabetes diagnosis was the result of their use of Lipitor. In his Order, Judge Seng ruled that staying the Lipitor lawsuit pending the possible transfer to the multidistrict litigation will not result in undue prejudice to plaintiffs. (Alanis v. Pfizer Inc., No. 1:14-365)

“Our Firm has heard from a number of individuals who have made allegations regarding the association between Lipitor and diabetes that echo those included in this case. We will be watching this matter closely,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit reviews to individuals who took the statin and later developed Type 2 diabetes.

Lipitor Diabetes Litigation
According to court documents, the California Lipitor lawsuit is one of more than 460 currently pending courts around the country that claim the statin drug can cause Type 2 diabetes. The majority of these claims have been filed in the multidistrict litigation underway in the U.S. District Court, Southern District of West Virginia. All of the claims allege that Pfizer Inc. was aware of the link between Lipitor and diabetes before modifying the drug’s label in February 2012 to reflect this risk, but concealed this information in order to protect sales of the medication. The lawsuits further claim that the 2012 label update was inadequate, and assert that many patients would never have used Lipitor had Pfizer provided adequate warnings regarding this potential side effect. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

Court records indicate that the litigation surrounding Lipitor has been growing since February 2012, when the U.S. Food & Drug Administration (FDA) ordered the manufacturers of statins to update their prescribing information with information about the drugs’ potential association with Type 2 diabetes. The request followed the publication of a study in JAMA: Internal Medicine the previous month which suggested that post-menopausal women treated with statins faced an increased risk of developing new-onset Type 2 diabetes. *

Since then, evidence linking Lipitor and diabetes has mounted. For example, the British Medical Journal reported in May 2013 that atorvastatin, the active ingredient in Lipitor, was linked to a 22 percent increased risk of new-onset diabetes.**

Individuals who allegedly developed Type 2 diabetes due to Lipitor may be entitled to compensation from Pfizer, Inc. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.

*, JAMA Internal Medicine, January 2012
**, BMJ, May 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website